Therapie der Migräneattacke und Migräneprophylaxe

Diener, H.-C.; Brune, Kay; Gerber, Wolf‐Dieter; Pfaffenrath, V.; Straube, Andreas

doi:10.1007/s004820070035

Cited by 29 publications

(28 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients, aged 18 years and older were documented if they carried a diagnosis of episodic migraine headaches and their diagnosis was based on the International Headache Society (IHS) criteria http://www.i-h-s.org/upload/ct_clas/ihc_II_main_no_print.pdf. The patients were prospectively followed-up for 6 and optionally for 12 months if migraine preventive therapy was indicated based on guidelines published by the German Neurological Society (DGN) http://www.ehf-org.org/Documents/Germany.pdf and the German Society for Headache (DGKM) [10]. Migraine headache, migraine attacks, and auras were defined based on the IHS definitions.…”

Section: Methodsmentioning

confidence: 99%

“…Migraine prevention not only reduces the frequency, severity, and duration of attacks, but was shown to reduce migraine-related socio-economic burden [9]. Pharmacological prevention of migraine is recommended by several professional societies if patients fulfill criteria for preventive treatment [10]. Multiple effective drugs are available, however, they differ in the level of scientific evidence to support their use in migraine prevention as well as in their clinical profile.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting

Nelles¹,

Schmitt²,

Humbert

et al. 2009

J Headache Pain

View full text Add to dashboard Cite

The majority of patients with migraine headaches are treated in non-specialized institutions though data on treatment outcomes are largely derived from tertiary care centers. The current non-interventional study explores efficacy and tolerability outcomes of patients with episodic migraines receiving topiramate as preventive agent in a general practice setting. A total of 366 patients (87% female, mean age 41.8 ± 11.6 years) were eligible for migraine prevention and treated with flexible dose topiramate for 6 months (core phase), and optionally for a total of 12 months (follow-up phase). Overall, 261 patients (77.7% of safety analysis set, SAF) completed the core phase. Reasons for discontinuation included adverse events (2.1%), lost to follow-up (1.8%), other reasons (1.5%), and end of therapy (0.3%) though in the majority of patients who discontinued no reasons were listed. The median daily dose at endpoint was 50 mg/day (range, 25–187.5 mg/day). The median days with migraine headaches decreased from 6.0 to 1.2 days (p < 0.001), median pain intensity score decreased from 17.0 to 3.2 points (p < 0.001). In women with reported menstruation-associated migraine, the median number of migraine attacks decreased from 4.0 to 0.9 (p < 0.001). Absenteeism as well as triptan use decreased significantly, and significant improvements in activities of daily living and quality of life were reported. The most frequently reported AEs were paraesthesia (4.2%) and nausea (3%). Results suggest that migraine prevention with topiramate in a general practice is generally well tolerated and associated with a significant improvement in migraine headaches and related functional impairment.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting

Nelles¹,

Schmitt²,

Humbert

et al. 2009

J Headache Pain

View full text Add to dashboard Cite

show abstract

“…Ihre geschätzte Präva-lenz liegt zwischen 8 und 16% [5,6]. Bei der Mehrzahl der Migränepatienten ist es ausreichend, ausschließlich die Attacken zu behandeln [7,8].Bei einer nicht zu vernachlässigenden Minderheit von Patienten ist jedoch eine prophylaktische Behandlung indiziert, da die Attacken zu häufig oder zu stark sind oder weil die Betroffenen schlecht auf die Akutbehandlung ansprechen. Für diese Patienten wird in gängigen Leitlinien und Über-sichten einschlägiger Fachgesellschaften bzw.…”

Section: Schlüsselwörterunclassified

“…Für diese Patienten wird in gängigen Leitlinien und Über-sichten einschlägiger Fachgesellschaften bzw. Kommissionen die Durchführung einer medikamentösen Prophylaxe empfohlen [7,8] …”

Section: Schlüsselwörterunclassified

Gibt es Evidenz für die Wirksamkeit komplementärmedizinischer Therapien für die Migräneprophylaxe?

Linde

2002

Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz

View full text Add to dashboard Cite

Complementary therapies are widely used and play an important role in the treatment of chronic pain syndromes. This review summarizes the evidences from randomized controlled trials for the effectiveness of a number of complementary therapies in migraine prophylaxis. The largest number of studies (a total of 15) is available for acupuncture. These studies are very heterogeneous in respect to interventions, methodological quality and outcome measurement, and the results are partly contradictory. The majority of trials, however, suggests that acupuncture is effective in migraine prophylaxis. The four existing, randomized and placebo-controlled trials on individualized homeopathy have shown conflicting results; clearly positive results have been reported only in the oldest, qualitatively least convincing study. Concerning herbal medicines the evidence is promising for extracts from Tanacetum parthenium (feverfew, five trials) and Petasites hybridus (one trial). Randomized trials on spinal manipulation for migraine prophylaxis have shown contradictory results. For neural therapy or complex strategies combining several complementary therapies only uncontrolled studies could be identified. In summary, there is promising evidence for the effectiveness of a number of complementary treatment options in migraine prophylaxis. Further research is clearly warranted.

show abstract

“…Für die Therapie primärer Kopfschmerzen existieren Empfehlungen der Deutschen Migräne-und Kopfschmerzgesellschaft [5,43], die auch bei der HIV-Infektion angewendet werden sollten [6]. Allerdings müssen bei HIV-Infizierten einige spezifische Besonderheiten beachtet werden.…”

Section: Therapieunclassified

Kopfschmerzen während der HIV-Infektion

Wibbeke¹,

Evers²,

Husstedt³

2000

Der Schmerz

View full text Add to dashboard Cite

The therapeutic management of headache during the HIV infection is the same as in non-infected subjects. However, tricyclic antidepressants and steroids as headache prophylactic agents are often more effective than in non-infected subjects and should be prescribed more generously. Some pharmacological interactions have to be considered, e. g. NSAID might increase the toxicity of antiretroviral substances.

show abstract

Therapie der Migräneattacke und Migräneprophylaxe

Cited by 29 publications

References 56 publications

Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting

Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting

Gibt es Evidenz für die Wirksamkeit komplementärmedizinischer Therapien für die Migräneprophylaxe?

Kopfschmerzen während der HIV-Infektion

Contact Info

Product

Resources

About